DeIPAs aren’t just consumers of KidneyDAO innovations—they’re validators.
Our biomarkers live or die on clinical utility.
Who better than decentralized physician groups to trial, validate, and scale them?
Our biomarkers live or die on clinical utility.
Who better than decentralized physician groups to trial, validate, and scale them?